VIENNA, Nov. 9, 2017 /PRNewswire/ -- SHL Group and fast-rising healthcare startup QuiO are pleased to announce a strategic partnership on digital technologies that will take the drug delivery industry into connected therapeutics.
SHL is a pioneer in advanced drug delivery systems based on human-centered design and functionality. It has a diverse portfolio of connected products and concepts that meet different patient and customer requirements.
New York-based startup QuiO, winner of the 2017 Accenture Global HealthTech Innovation Challenge, is at the vanguard of digital technologies that allow injectable therapies to reach their full potential. QuiO technologies include the ConnectedRx((TM)), a first-of-its-kind cloud-based solution for patient support.
SHL and QuiO believe that connectivity is the key to taking user experience to the next level. The idea of the device as not only a drug carrier, but as a data collector, opens up unique opportunities to support patient adherence and monitor treatment outcomes.
The strategic partnership is a valuable match that will add to SHL's wide range of products and provide a sophisticated software platform. QuiO's fully integrated solution combines novel device concepts, software and services and is expected to take patient care to the next level.
"SHL has pushed to stay at the leading edge of advanced drug delivery for more than 20 years. As the healthcare industry embraces digital and people increasingly take their treatment into their own hands, our natural next step is connectivity that seamlessly captures high-quality data to form a detailed picture of the patient to improve clinical decision-making," SHL Group founder and CEO Roger Samuelsson said.
QuiO CEO Alexander Dahmani said: "QuiO is excited to contribute hardware technology and provide the full software-stack for SHL's connected devices. Our ConnectedRx((TM)) solution captures data directly from medical devices, structures and stores it in a secure cloud environment, and serves it to a suite of powerful applications that enable patients, clinicians, and customers to benefit from the data."
For SHL, partnering with QuiO is an important milestone that will provide entrepreneurial spirit and excellent capabilities to support its ambitions to lead the digital healthcare industry.
QuiO is a connected therapeutics company that provides software and services enabled by smart medication devices. The company's solution helps chronic disease patients succeed on long-term therapies, and helps stakeholders track the real-world performance of these therapies. To learn more about QuiO, please visit www.quio.com [http://www.quio.com/].
About SHL Group
SHL is a world-leading solution provider in the design, development and manufacturing of advanced drug delivery devices such as auto injectors and pen injectors. With locations in Taiwan, Sweden, China and the U.S., it develops product enhancements and breakthrough drug delivery solutions for pharma and biotech clients globally. Visit shl.group [http://shl.group/] for more information.
Photo - https://mma.prnewswire.com/media/600821/SHL_QuiO_image.jpg [https://mma.prnewswire.com/media/600821/SHL_QuiO_image.jpg]
CONTACT: Alexander Dahmani, QuiO co-founder and CEO, T: +1-646-600 9979, email@example.com; Per Bjorkman, Managing director of SHL Life, T: +46-8-462-18-46, firstname.lastname@example.org
Web site: http://shl.group/